Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
10
self-reported 2–10 band
Founded
Not recorded
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
5
Grant · Oct 2022 · US$ 1.0M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
CYNATA THERAPEUTICS LIMITED
ABN98104037372
Legal entities
Show as table · Cynata Therapeutics: 1 registry entity
| CYNATA THERAPEUTICS LIMITED | ABN 98104037372 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.
Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Specialties
All 3 specialties
- Stem cells
- MSCs
- iPSCs
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU100 Cubitt St; L3; Cremorne, Victoria 3121Primary
Grid intelligence Members
Funding
Rounds5
Round typeGrant · non-equity funding
Amount (USD)1,000,000
Stage rank1
Investors named1
Since last round3 yr 2 mo
Funding
Show as table · 5 funding rounds
| Rounds | 5 |
|---|---|
| Axis | 2023 to 2026 |
| Grant · 26 Oct 2022 | US$ 1.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Cynata Therapeutics?
One Victoria entity on the ABR: CYNATA THERAPEUTICS LIMITED (ABN 98 104 037 372), high confidence.
How many people work at Cynata Therapeutics?
10 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Cynata Therapeutics have offices?
One address on record, Australia only. Primary: 100 Cubitt St, L3, Cremorne, Victoria 3121.
Has Cynata Therapeutics raised funding?
Five rounds. Latest 26 October 2022: grant, US$1,000,000, investor National Health and Medical Research Council.
What does Cynata Therapeutics list as its specialties?
Three tags on the brand's own list, among them Stem cells, MSCs and iPSCs.
Which companies are listed alongside Cynata Therapeutics?
21 profiles list Cynata Therapeutics as a peer — 94th percentile in Biotechnology Research. It lists ten peers of its own. Orthocell Ltd and Mesoblast Limited list it back.